Two Sigma Securities’s Genetic Technologies Ltd. GENE Stock Holding History

Two Sigma Securities’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-14,457	Closed	-$11.2K	–	3516
2024 Q3	$11.2K	Buy	+14,457	New	+$12.9K	﹤0.01%	2574
2023 Q4	–	Sell	-3,169	Closed	-$12.1K	–	3752
2023 Q3	$12.1K	Buy	3,169 +188	+6%	+$767	﹤0.01%	2663
2023 Q2	$12.4K	Buy	2,981 +926	+45%	+$4.59K	﹤0.01%	2565
2023 Q1	$11.9K	Buy	+2,055	New	+$12K	﹤0.01%	2432
2022 Q3	–	Sell	-2,336	Closed	-$14K	–	3231
2022 Q2	$14K	Buy	+2,336	New	+$16.9K	﹤0.01%	2008
2022 Q1	–	Sell	-2,018	Closed	-$19K	–	2624
2021 Q4	$19K	Buy	+2,018	New	+$25.9K	﹤0.01%	1417
2021 Q2	–	Sell	-4,737	Closed	-$99K	–	1773
2021 Q1	$99K	Buy	+4,737	New	+$108K	0.01%	697
2017 Q1	–	Sell	-2,450	Closed	-$53K	–	1163
2016 Q4	$53K	Buy	+2,450	New	+$67.9K	0.02%	597

Other funds holding GENE

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Two Sigma Securities's GENE Position: Q4 2024 in Review

Two Sigma Securities sold out of Genetic Technologies Ltd. (GENE) in Q4 2024, closing a stake of 14,457 shares — an estimated $11.2K sold.

Two Sigma Securities first reported a position in GENE in Q4 2016 and held it in 8 quarters. The position peaked at $99K in Q1 2021. 1 fund tracked by Wall St. Rank holds GENE as of Q4 2024.

Two Sigma Securities reported no remaining Genetic Technologies Ltd. position as of Q4 2024 after selling out during the quarter.
Two Sigma Securities sold 14,457 Genetic Technologies Ltd. shares in Q4 2024, an estimated $11.2K.
Two Sigma Securities first reported a position in Genetic Technologies Ltd. in Q4 2016 and held it in 8 quarters.
Two Sigma Securities's Genetic Technologies Ltd. position peaked at $99K in Q1 2021.
1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2024.

Based on Two Sigma Securities's 13F filing for Q4 2024, filed 14 Feb 2025.